# Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

> **NCT00542425** · PHASE2 · COMPLETED · sponsor: **Radius Health, Inc.** · enrollment: 222 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** teriparatide
- **DRUG:** Placebo
- **DRUG:** BA058 20 µg
- **DRUG:** BA058 40 µg
- **DRUG:** BA058 80 µg

## Key facts

- **NCT ID:** NCT00542425
- **Lead sponsor:** Radius Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2017-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542425, "Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00542425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*